158 related articles for article (PubMed ID: 38425338)
1. Case report: Enfortumab vedotin induced refractory DKA and multi organ failure - a rare fatal adverse event.
Kapoor AK; Ellis CS; Pandey D; Allison DB; Myint ZW
Front Oncol; 2024; 14():1332478. PubMed ID: 38425338
[TBL] [Abstract][Full Text] [Related]
2. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
3. Refractory insulin resistance and hemophagocytic lymphohistiocytosis following enfortumab vedotin treatment: A case report.
Rossignon P; Nguyen LDK; Boegner P; Ku J; Herpain A
Mol Clin Oncol; 2024 Jun; 20(6):44. PubMed ID: 38799283
[TBL] [Abstract][Full Text] [Related]
4. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS; Henderson N; James M; Natesan D; Freeman D; Nizam A; Su CT; Khaki AR; Osterman CK; Glover MJ; Chiang R; Makrakis D; Talukder R; Lemke E; Olsen TA; Jain J; Jang A; Ali A; Jindal T; Chou J; Friedlander TW; Hoimes C; Basu A; Zakharia Y; Barata PC; Bilen MA; Emamekhoo H; Davis NB; Shah SA; Milowsky MI; Gupta S; Campbell MT; Grivas P; Sonpavde GP; Kilari D; Alva AS
Cancer; 2022 Mar; 128(6):1194-1205. PubMed ID: 34882781
[TBL] [Abstract][Full Text] [Related]
6. Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report.
Atemnkeng F; Aguilar F; Gupta S; Chugh S; Klein M
Kidney Med; 2023 Dec; 5(12):100737. PubMed ID: 38028029
[TBL] [Abstract][Full Text] [Related]
7. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
Zschäbitz S; Biernath N; Hilser T; Höllein A; Zengerling F; Cascucelli J; Paffenholz P; Seidl D; Lutz C; Schlack K; Kingreen D; Klümper N; Ivanyi P; von Amsberg G; Heers H; Roghmann F; Tauber RL; Cathomas R; Hofer L; Niegisch G; Klee M; Ehrenberg R; Hassler A; Hadaschik BA; Grünwald V; Darr C
Eur Urol Open Sci; 2023 Jul; 53():31-37. PubMed ID: 37441344
[TBL] [Abstract][Full Text] [Related]
8. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study.
Morikawa T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Iida K; Isobe T; Noda Y; Shimizu N; Aoki M; Gonda M; Banno R; Kubota H; Ando R; Umemoto Y; Kawai N; Yasui T
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730675
[TBL] [Abstract][Full Text] [Related]
9. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
10. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
Wong RL; Yu EY
Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
[TBL] [Abstract][Full Text] [Related]
11. Enfortumab Vedotin-related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature.
Vlachou E; Matoso A; McConkey D; Jing Y; Johnson BA; Hahn NM; Hoffman-Censits J
Eur Urol Open Sci; 2023 Mar; 49():100-103. PubMed ID: 36820243
[TBL] [Abstract][Full Text] [Related]
12. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
13. Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin.
Hanna KS
J Adv Pract Oncol; 2020; 11(4):412-417. PubMed ID: 33604101
[TBL] [Abstract][Full Text] [Related]
14. Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Kawahara T; Hasizume A; Uemura K; Yamaguchi K; Ito H; Takeshima T; Hasumi H; Teranishi JI; Ousaka K; Makiyama K; Uemura H
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686503
[TBL] [Abstract][Full Text] [Related]
15. Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis.
Collette KR; Myint ZW; Parasramka SV; Ellis CS
Front Oncol; 2022; 12():892793. PubMed ID: 35692805
[TBL] [Abstract][Full Text] [Related]
16. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.
Rosenberg JE; O'Donnell PH; Balar AV; McGregor BA; Heath EI; Yu EY; Galsky MD; Hahn NM; Gartner EM; Pinelli JM; Liang SY; Melhem-Bertrandt A; Petrylak DP
J Clin Oncol; 2019 Oct; 37(29):2592-2600. PubMed ID: 31356140
[TBL] [Abstract][Full Text] [Related]
17. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
[TBL] [Abstract][Full Text] [Related]
18. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
Jain RK; Skelton WP; Zhang J
Cancer Manag Res; 2020; 12():8379-8386. PubMed ID: 32982431
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
